文献速递系统性红斑狼疮

未接种和已接种疫苗的系统性红斑狼疮患者COVID-19风险:一项一般人群研究

Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study.
PubMed 文献 · RMD Open · 2023-01-01

基于健康改善网络数据的队列研究比较了系统性红斑狼疮(SLE)患者与一般人群的SARS-CoV-2感染及严重后遗症风险。未接种队列中,SLE患者感染、住院、死亡及合并严重结局的风险均高于一般人群;而在接种疫苗人群中,随访9个月内未观察到统计学显著差异。

要点

  • 未接种SLE患者SARS-CoV-2感染风险高于一般人群(调整HR 1.28,95%CI 1.03至1.59)。
  • 未接种SLE患者COVID-19住院、死亡及合并严重结局风险亦高于一般人群。
  • 接种疫苗的SLE患者与接种疫苗的一般人群在9个月随访内无统计学显著差异。

核心结论

  • 未接种疫苗的SLE患者较一般人群有更高的SARS-CoV-2感染及其严重后遗症风险,而接种疫苗人群中未观察到此种差异。
  • 研究结果表明COVID-19疫苗接种为大多数SLE患者提供了足够的保护,避免COVID-19突破性感染及其严重后遗症。

研究设计与样本

  • 利用健康改善网络(The Health Improvement Network)数据进行的队列研究。
  • 纳入年龄18至90岁、既往无SARS-CoV-2感染记录的个体,比较SLE患者与一般人群的SARS-CoV-2感染及严重后遗症风险。
  • 采用暴露评分重叠加权Cox比例风险模型,按COVID-19疫苗接种状态估计SARS-CoV-2感染及严重后遗症的发生率和HR。

主要发现

  • 未接种队列中识别出3245例SLE患者和1 755 034例非SLE个体。
  • 未接种队列中,SLE患者与一般人群的SARS-CoV-2感染率分别为每1000人月10.95和8.50,调整HR为1.28(95%CI 1.03至1.59)。
  • 未接种队列中,SLE患者与一般人群的COVID-19住院率分别为每1000人月3.21和1.77,调整HR为1.82(95%CI 1.21至2.74)。
  • 未接种队列中,SLE患者与一般人群的COVID-19死亡率分别为每1000人月1.16和0.53,调整HR为2.16(95%CI 1.00至4.79)。
  • 未接种队列中,SLE患者与一般人群的合并严重结局发生率分别为每1000人月3.86和2.18,调整HR为1.78(95%CI 1.21至2.61)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of SARS-CoV-2 infection and its related severe sequelae between patients with systemic lupus erythematosus (SLE) and the general population according to COVID-19 vaccination status. METHODS: We performed cohort studies using data from The Health Improvement Network to compare the risks of SARS-CoV-2 infection and severe sequelae between patients with SLE and the general population. Individuals aged 18-90 years with no previously documented SARS-CoV-2 infection were included. We estimated the incidence rates and HRs of SARS-CoV-2 infection and severe sequelae between patients with SLE and the general population according to COVID-19 vaccination status using exposure score overlap weighted Cox proportional hazards model. RESULTS: We identified 3245 patients with SLE and 1 755 034 non-SLE individuals from the unvaccinated cohort. The rates of SARS-CoV-2 infection, COVID-19 hospitalisation, COVID-19 death and combined severe outcomes per 1000 person-months were 10.95, 3.21, 1.16 and 3.86 among patients with SLE, and 8.50, 1.77, 0.53 and 2.18 among general population, respectively. The corresponding adjusted HRs were 1.28 (95% CI: 1.03 to 1.59), 1.82 (95% CI: 1.21 to 2.74), 2.16 (95% CI: 1.00 to 4.79) and 1.78 (95% CI: 1.21 to 2.61). However, no statistically significant differences were observed between vaccinated patients with SLE and vaccinated general population over 9 months of follow-up. CONCLUSION: While unvaccinated patients with SLE were at higher risk of SARS-CoV-2 infection and its severe sequelae than the general population, no such difference was observed among vaccinated population. The findings indicate that COVID-19 vaccination provides an adequate protection to most patients with SLE from COVID-19 breakthrough infection and its severe sequelae.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Jiang X, Sparks J, Wallace Z, et al. Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study. RMD Open. 2023. PMID: 36889799. doi:10.1136/rmdopen-2022-002839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。